Tuberculosis Immunopathology: the Neglected Role of Extracellular Matrix Destruction

Overview

Journal Sci Transl Med

Specialties General Medicine
Science

Date 2011 Feb 25

PMID 21346167

Citations 55

Authors

Paul T Elkington

Jeanine M DArmiento

Jon S Friedland

Affiliations

Soon will be listed here.

Abstract

The extracellular matrix in the lung must be destroyed for Mycobacterium tuberculosis--the agent that causes tuberculosis (TB)--to spread. The current paradigm proposes that this destruction occurs as a result of the action of proinflammatory cytokines, chemokines, immune cells, and lipids that mediate TB-associated necrosis in the lung. However, this view neglects the fact that lung matrix can only be degraded by proteases. We propose an original conceptual framework of TB immunopathology that may lead directly to treatments that involve inhibition of matrix metalloproteinase activity to hinder matrix destruction and reduce the morbidity and mortality associated with TB.

Citing Articles

The advances in adjuvant therapy for tuberculosis with immunoregulatory compounds.

Mi J, Wu X, Liang J Front Microbiol. 2024; 15:1380848.

PMID: 38966394 PMC: 11222340. DOI: 10.3389/fmicb.2024.1380848.

Myeloid cell expression of CD200R is modulated in active TB disease and regulates infection in a biomimetic model.

Ahmed M, Tezera L, Herbert N, Chambers M, Reichmann M, Nargan K Front Immunol. 2024; 15:1360412.

PMID: 38745652 PMC: 11091283. DOI: 10.3389/fimmu.2024.1360412.

3D Hydrogel Culture System Recapitulates Key Tuberculosis Phenotypes and Demonstrates Pyrazinamide Efficacy.

Gupta V, Vaishnavi V, Arrieta-Ortiz M, P S A, K M J, Jeyasankar S Adv Healthc Mater. 2024; 14(5):e2304299.

PMID: 38655817 PMC: 7616495. DOI: 10.1002/adhm.202304299.

Integrated plasma proteomics identifies tuberculosis-specific diagnostic biomarkers.

Schiff H, Walker N, Ugarte-Gil C, Tebruegge M, Manousopoulou A, Garbis S JCI Insight. 2024; 9(8).

PMID: 38512356 PMC: 11141874. DOI: 10.1172/jci.insight.173273.

Doxycycline as a Potential MMP-1 Inhibitor for the Treatment of Spondylitis Tuberculosis: A Study in Rabbit Model.

Siregar O, Lelo A, Rahyussalim A, Ilyas S, Benny , Kurniawati T Biomed Res Int. 2023; 2023:7421325.

PMID: 36743515 PMC: 9897918. DOI: 10.1155/2023/7421325.

References

Desvignes L, Ernst J . Interferon-gamma-responsive nonhematopoietic cells regulate the immune response to Mycobacterium tuberculosis. Immunity. 2010; 31(6):974-85. PMC: 2807991. DOI: 10.1016/j.immuni.2009.10.007. View

Russell D . Who puts the tubercle in tuberculosis?. Nat Rev Microbiol. 2006; 5(1):39-47. DOI: 10.1038/nrmicro1538. View

Coussens L, Fingleton B, Matrisian L . Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science. 2002; 295(5564):2387-92. DOI: 10.1126/science.1067100. View

van der Sar A, Spaink H, Zakrzewska A, Bitter W, Meijer A . Specificity of the zebrafish host transcriptome response to acute and chronic mycobacterial infection and the role of innate and adaptive immune components. Mol Immunol. 2009; 46(11-12):2317-32. DOI: 10.1016/j.molimm.2009.03.024. View

Russell D, Barry 3rd C, Flynn J . Tuberculosis: what we don't know can, and does, hurt us. Science. 2010; 328(5980):852-6. PMC: 2872107. DOI: 10.1126/science.1184784. View

Hunter R, Jagannath C, Actor J . Pathology of postprimary tuberculosis in humans and mice: contradiction of long-held beliefs. Tuberculosis (Edinb). 2007; 87(4):267-78. DOI: 10.1016/j.tube.2006.11.003. View

Meintjes G, Lawn S, Scano F, Maartens G, French M, Worodria W . Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008; 8(8):516-23. PMC: 2804035. DOI: 10.1016/S1473-3099(08)70184-1. View

Dannenberg Jr A, Sugimoto M . Liquefaction of caseous foci in tuberculosis. Am Rev Respir Dis. 1976; 113(3):257-9. DOI: 10.1164/arrd.1976.113.3.257. View

Guyot-Revol V, Innes J, Hackforth S, Hinks T, Lalvani A . Regulatory T cells are expanded in blood and disease sites in patients with tuberculosis. Am J Respir Crit Care Med. 2005; 173(7):803-10. DOI: 10.1164/rccm.200508-1294OC. View

10.

North R, Jung Y . Immunity to tuberculosis. Annu Rev Immunol. 2004; 22:599-623. DOI: 10.1146/annurev.immunol.22.012703.104635. View

11.

Cooper A . Cell-mediated immune responses in tuberculosis. Annu Rev Immunol. 2009; 27:393-422. PMC: 4298253. DOI: 10.1146/annurev.immunol.021908.132703. View

12.

Golub L, McNamara T, Ryan M, KOHUT B, Blieden T, Payonk G . Adjunctive treatment with subantimicrobial doses of doxycycline: effects on gingival fluid collagenase activity and attachment loss in adult periodontitis. J Clin Periodontol. 2001; 28(2):146-56. DOI: 10.1034/j.1600-051x.2001.028002146.x. View

13.

Hemmings F, Farhan M, Rowland J, Banken L, Jain R . Tolerability and pharmacokinetics of the collagenase-selective inhibitor Trocade in patients with rheumatoid arthritis. Rheumatology (Oxford). 2001; 40(5):537-43. DOI: 10.1093/rheumatology/40.5.537. View

14.

Kessenbrock K, Plaks V, Werb Z . Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010; 141(1):52-67. PMC: 2862057. DOI: 10.1016/j.cell.2010.03.015. View

15.

Nuttall R, Sampieri C, Pennington C, Gill S, Schultz G, Edwards D . Expression analysis of the entire MMP and TIMP gene families during mouse tissue development. FEBS Lett. 2004; 563(1-3):129-34. DOI: 10.1016/S0014-5793(04)00281-9. View

16.

Nedeltchev G, Raghunand T, Jassal M, Lun S, Cheng Q, Bishai W . Extrapulmonary dissemination of Mycobacterium bovis but not Mycobacterium tuberculosis in a bronchoscopic rabbit model of cavitary tuberculosis. Infect Immun. 2008; 77(2):598-603. PMC: 2632025. DOI: 10.1128/IAI.01132-08. View

17.

Kaplan G, Post F, Moreira A, Wainwright H, Kreiswirth B, Tanverdi M . Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun. 2003; 71(12):7099-108. PMC: 308931. DOI: 10.1128/IAI.71.12.7099-7108.2003. View

18.

Andries K, Verhasselt P, Guillemont J, Gohlmann H, Neefs J, Winkler H . A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. 2004; 307(5707):223-7. DOI: 10.1126/science.1106753. View

19.

Hu J, Van den Steen P, Sang Q, Opdenakker G . Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov. 2007; 6(6):480-98. DOI: 10.1038/nrd2308. View

20.

Elkington P, Nuttall R, Boyle J, OKane C, Horncastle D, Edwards D . Mycobacterium tuberculosis, but not vaccine BCG, specifically upregulates matrix metalloproteinase-1. Am J Respir Crit Care Med. 2005; 172(12):1596-604. DOI: 10.1164/rccm.200505-753OC. View